 |
|
Utility Values and Age-related Macular Degeneration
Gary C. Brown, MD, MBA;
Sanjay Sharma, MD, MSc(Epid);
Melissa M. Brown, MN, MD, MBA;
Jonathan Kistler, MD
Arch Ophthalmol. 2000;118:47-51.
Objective To ascertain the utility values associated with age-related macular degeneration and varying degrees of visual loss.
Design A cross-sectional study.
Participants Eighty white patients with unilateral or bilateral age-related macular degeneration in 1 or both eyes, and visual loss to a minimum of the 20/40 level in at least 1 eye.
Main Outcome Measures Utility values were measured in 5 groups according to the visual acuity in the better-seeing eye, 1 (20/20 to 20/25), 2 (20/30 to 20/50), 3 (20/60 to 20/100), 4 (20/200 to 20/400), and 5 (counting fingers to light perception), using the time trade-off and the standard gamble methods. Conventionally assigned anchor utility values were 1.0 for perfect health and 0.0 for death.
Results The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method. Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50). Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.
Conclusion Age-related macular degeneration causes a substantial decrease in patient utility values and is highly dependent on the degree of visual loss in the better-seeing eye.
From the Retina Vascular Unit (Drs G. C. Brown and Kistler) and the Cataract and Primary Eye Care Service (Dr M. M. Brown), Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pa; the Departments of Ophthalmology and Epidemiology, Queens Medical College, Kingston, Ontario (Dr Sharma); and the Center for Evidence-Based Healthcare, Flourtown, Pa (Drs G. C. Brown, Sharma, and M. M. Brown).
RELATED ARTICLE
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2000;118(1):152-153.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The effect of comorbidities upon ocular and systemic health-related quality of life
Real et al.
Br. J. Ophthalmol. 2008;92:770-774.
ABSTRACT
| FULL TEXT
Evaluation of Quality of Life and Priorities of Patients with Glaucoma
Aspinall et al.
IOVS 2008;49:1907-1915.
ABSTRACT
| FULL TEXT
Formal and informal care utilisation amongst elderly persons with visual impairment
Ke et al.
Br. J. Ophthalmol. 2007;91:1279-1281.
ABSTRACT
| FULL TEXT
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Raftery et al.
Br. J. Ophthalmol. 2007;91:1244-1246.
ABSTRACT
| FULL TEXT
Health-Related Quality of Life and Utility in Patients With Age-Related Macular Degeneration
Sahel et al.
Arch Ophthalmol 2007;125:945-951.
ABSTRACT
| FULL TEXT
Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration
Aspinall et al.
Br. J. Ophthalmol. 2007;91:766-772.
ABSTRACT
| FULL TEXT
Vision and Quality of Life: The Development of a Utility Measure
Misajon et al.
IOVS 2005;46:4007-4015.
ABSTRACT
| FULL TEXT
The Impact of Age-Related Macular Degeneration on Health Status Utility Values
Espallargues et al.
IOVS 2005;46:4016-4023.
ABSTRACT
| FULL TEXT
Patients' Perceptions of the Value of Current Vision: Assessment of Preference Values Among Patients With Subfoveal Choroidal Neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6
Submacular Surgery Trials Research Group
Arch Ophthalmol 2004;122:1856-1867.
ABSTRACT
| FULL TEXT
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
Smith et al.
Br. J. Ophthalmol. 2004;88:1107-1112.
ABSTRACT
| FULL TEXT
Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration
Hopley et al.
Br. J. Ophthalmol. 2004;88:982-987.
ABSTRACT
| FULL TEXT
Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants
Hopley et al.
Br. J. Ophthalmol. 2004;88:450-454.
ABSTRACT
| FULL TEXT
Preferences and Willingness to Pay for Health States Prevented by Pneumococcal Conjugate Vaccine
Prosser et al.
Pediatrics 2004;113:283-290.
ABSTRACT
| FULL TEXT
Utilities associated with diabetic retinopathy: results from a Canadian sample
Sharma et al.
Br. J. Ophthalmol. 2003;87:259-261.
ABSTRACT
| FULL TEXT
Utility values and myopia in teenage school students
Saw et al.
Br. J. Ophthalmol. 2003;87:341-345.
ABSTRACT
| FULL TEXT
Prevention of Herpes Simplex Virus Eye Disease: A Cost-effectiveness Analysis
Lairson et al.
Arch Ophthalmol 2003;121:108-112.
ABSTRACT
| FULL TEXT
Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients
Sharma et al.
Br. J. Ophthalmol. 2002;86:493-496.
ABSTRACT
| FULL TEXT
Quality of Life With Visual Acuity Loss From Diabetic Retinopathy and Age-Related Macular Degeneration
Brown et al.
Arch Ophthalmol 2002;120:481-484.
ABSTRACT
| FULL TEXT
Quality of life and systemic comorbidities in patients with ophthalmic disease
Brown et al.
Br. J. Ophthalmol. 2002;86:8-11.
ABSTRACT
| FULL TEXT
How Often Should Patients With Diabetes Be Screened for Retinopathy?
Javitt et al.
JAMA 2000;284:437-439.
FULL TEXT
|
